ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
PSMA-GCK01: A Generator-Based
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Evaluation of the biodistribution of [EJNMMI research · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.EJNMMI research · 2026Article
- Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025Review
- Maleic anhydride derived diphosphines: adaptable chelators for receptor-targetedChemical science · 2025Article
- Chelator Optimization and Therapeutic Potential ofACS medicinal chemistry letters · 2025Article
- Recent advances in theranostics and oncology PET: emerging radionuclides and targets.Annals of nuclear medicine · 2025Review
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Development of [Journal of medicinal chemistry · 2025Article
- Prostate-specific membrane antigen radioguided surgery in prostate cancer: A narrative review.Central European journal of urology · 2025Review
- Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [Molecular imaging and biology · 2024Article
- Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.Cancers · 2023Review
Corrections and comments
- Commented on byPotential of2023
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) theranostics have been introduced with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.